Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma

doi:10.4254/wjh.v14.i8.1608

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3495)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-6) series.

Item

Count

PDF

227

WORD

HTML

1660

Figures (1-5)

343

Tables (1-6)

332

Sum=2622

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

294

Download

579

Sum=873

Aug 27, 2022 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Aug 27, 2022; 14(8): 1608-1620
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1608

Table 4 Evolution of World Health Organization performance status

WHO PS	2 mo	4 mo
Worse PS	8 (29.6%)	5 (21.7%)
Stable PS	14 (51.9%)	13 (56.5%)
Better PS	5 (18.5%)	5 (21.7%)
Total	27 (100%)	23 (100%)
Death	2	6

WHO PS: World Health Organization performance status.

Citation: De Wilde N, Vonghia L, Francque S, De Somer T, Bagdadi A, Staub E, Lambrechts J, Bucalau AM, Verset G, Van Steenkiste C. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol 2022; 14(8): 1608-1620
URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1608.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1608